NasdaqGS:HALOBiotechs
How Investors May Respond To Halozyme Therapeutics (HALO) Revenue Growth And Impairment-Driven Quarterly Loss
In February 2026, Halozyme Therapeutics reported Q4 and full-year 2025 results showing revenue rising to US$451.77 million for the quarter and US$1.40 billion for the year, but a quarterly net loss of US$141.59 million driven in part by a US$48.70 million intangible asset impairment.
Despite the earnings miss linked to acquisition-related costs and write-downs, Halozyme reaffirmed 2026 revenue guidance of US$1.71 billion to US$1.81 billion, underscoring management’s confidence in its...